Display options
Cite
Kolovos S, Nador G, Kishore B, et al. Unplanned admissions for patients with myeloma in the UK: Low frequency but high costs. J Bone Oncol. 2019;17:100243doi: 10.1016/j.jbo.2019.100243.
Kolovos, S., Nador, G., Kishore, B., Streetly, M., Rabin, N. K., Chantry, A. D., Yong, K., Ashcroft, J., Bowcock, S., Drayson, M. T., Ramasamy, K., Prieto-Alhambra, D., Cooper, C., Javaid, M. K., & Pinedo-Villanueva, R. (2019). Unplanned admissions for patients with myeloma in the UK: Low frequency but high costs. Journal of bone oncology, 17100243. https://doi.org/10.1016/j.jbo.2019.100243
Kolovos, Spyros, et al. "Unplanned admissions for patients with myeloma in the UK: Low frequency but high costs." Journal of bone oncology vol. 17 (2019): 100243. doi: https://doi.org/10.1016/j.jbo.2019.100243
Kolovos S, Nador G, Kishore B, Streetly M, Rabin NK, Chantry AD, Yong K, Ashcroft J, Bowcock S, Drayson MT, Ramasamy K, Prieto-Alhambra D, Cooper C, Javaid MK, Pinedo-Villanueva R. Unplanned admissions for patients with myeloma in the UK: Low frequency but high costs. J Bone Oncol. 2019 Jun 07;17:100243. doi: 10.1016/j.jbo.2019.100243. eCollection 2019 Aug. PMID: 31223562; PMCID: PMC6579752.
Copy Download .nbib Format: NLM
Share it on

J Bone Oncol. 2019 Jun 07;17:100243. doi: 10.1016/j.jbo.2019.100243. eCollection 2019 Aug.

Unplanned admissions for patients with myeloma in the UK: Low frequency but high costs.

Journal of bone oncology

Spyros Kolovos, Guido Nador, Bhuvan Kishore, Matthew Streetly, Neil K Rabin, Andrew D Chantry, Kwee Yong, John Ashcroft, Stella Bowcock, Mark T Drayson, Karthik Ramasamy, Daniel Prieto-Alhambra, Cyrus Cooper, M Kassim Javaid, Rafael Pinedo-Villanueva

Affiliations

  1. Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Old Rd, Oxford OX3 7LD, UK.
  2. Oxford University Hospitals NHS Trust, Oxford, UK.
  3. Heart of England NHS Foundation Trust, Birmingham, UK.
  4. Guy's and St. Thomas' NHS Foundation Trust and King's College London, London, UK.
  5. Department of Haematology, University College London Hospitals NHS Foundation Trust, London, UK.
  6. Department of Oncology and Metabolism, Medical School, University of Sheffield, Sheffield, UK.
  7. Department of Haematology, Sheffield Teaching Hospitals NHS Foundation Trust, Royal Hallamshire Hospital, Sheffield, UK.
  8. UCL Cancer Institute, London, UK.
  9. Department of Haematology, Mid Yorkshire NHS Trust, Wakefield, UK.
  10. King's College Hospital NHS Trust, London, UK.
  11. Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.
  12. Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology, and Musculoskeletal Sciences, University of Oxford, Oxford, UK.
  13. Grup de Recerca en Malalties Prevalents de l'Aparell Locomotor Research Group and CIBERFes, University Institute for Primary CareResearch Jordi Gol, Universitat Autonoma de Barcelona and Instituto de Salud Carlos III, Barcelona, Spain.
  14. MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, UK.
  15. NIHR Southampton Biomedical Research Centre, University of Southampton and University Hospital Southampton NHS Foundation Trust, Southampton, UK.
  16. NIHR Oxford Biomedical Research Centre, University of Oxford, Oxford, UK.

PMID: 31223562 PMCID: PMC6579752 DOI: 10.1016/j.jbo.2019.100243

Abstract

BACKGROUND: Multiple myeloma (MM) is associated with high healthcare resource utilisation and increasing hospitalisation rates. The aim of this study was to characterise the hospital use by patients with MM in the English National Health Service (NHS).

METHODS: Routinely-collected aggregate data about all NHS-funded hospital admissions of patients with MM were analysed. Data were obtained from the English Hospital Episodes Statistics on admissions between 1 April 2014 and 31 March 2018.

RESULTS: A total of 754,345 admissions were reported over four years, equivalent to a mean of 188,586 admissions per year. Of the 41,845 patients admitted during this period, 42% were women and 58% men. From the total admissions, 90% were elective and 10% unplanned. Mean annual estimated costs over the period were £46 million for elective and £56 million for unplanned admissions. The number of elective admissions increased by 4.5% with costs increasing 1.5% per year; for unplanned admissions, these figures were 4.1% and 9.0%, respectively.

CONCLUSIONS: MM is associated with a significant number of hospital admissions and NHS costs. The majority of the hospital admissions are elective, but the highest burden in terms of costs relates to unplanned admissions, with numbers increasing over time.

Keywords: Costs; Elective admissions; Multiple myeloma; Unplanned admissions

References

  1. Eur J Haematol. 2005 Feb;74(2):136-43 - PubMed
  2. Hematology Am Soc Hematol Educ Program. 2005;:353-9 - PubMed
  3. Blood. 2008 Mar 1;111(5):2516-20 - PubMed
  4. Hematol Oncol Clin North Am. 2007 Dec;21(6):1231-46, xi - PubMed
  5. Neoplasma. 2008;55(4):350-5 - PubMed
  6. Oncologist. 2010;15(1):6-25 - PubMed
  7. J Natl Compr Canc Netw. 2010 Feb;8 Suppl 1:S4-S12 - PubMed
  8. Br J Cancer. 2016 May 24;114(11):1286-92 - PubMed
  9. Leukemia. 2017 Sep;31(9):1915-1921 - PubMed
  10. Eur J Haematol. 2017 Aug;99(2):119-132 - PubMed
  11. Int J Epidemiol. 2017 Aug 1;46(4):1093-1093i - PubMed
  12. Eur Urol Focus. 2018 Jul;4(4):586-590 - PubMed
  13. Leuk Lymphoma. 2018 Apr;59(4):941-949 - PubMed
  14. Int J Epidemiol. 2017 Dec 1;46(6):1786-1796 - PubMed
  15. Int J Cancer. 2018 Aug 15;143(4):773-781 - PubMed
  16. JAMA Oncol. 2018 Sep 1;4(9):1221-1227 - PubMed

Publication Types

Grant support